论文部分内容阅读
目的:观察分析小儿咳嗽变异型哮喘患儿应用孟鲁司特钠联合氯雷他定治疗效果。方法:选取我院于2014年2月至2015年2月期间收治的小儿咳嗽变异型哮喘患儿98例作为研究对象,按入院顺序的不同,分为对照组(n=49例)和观察组(n=49例),给予对照组患儿常规治疗,观察组在常规治疗的基础上加以孟鲁司特钠联合氯雷他定治疗,比较两组治疗效果。结果:观察组治疗总有效率为97.96%(48/49),对照组有效率为73.47%(36/49),差异有统计学意义(P<0.05);观察组患儿在哮喘持续发作时间、咳嗽消失时间以及哮鸣音和体征消失时间均显著短于对照组(P<0.05)。结论:对于小儿咳嗽变异型哮喘患儿,给予孟鲁司特钠联合氯雷他定治疗较常规治疗更有效,可以显著提高治疗效果和改善临床症状,值得临床推广和应用。
Objective: To observe the effect of montelukast sodium and loratadine in pediatric cough variant asthma. Methods: A total of 98 children with cough variant asthma were enrolled in our hospital from February 2014 to February 2015. The subjects were divided into control group (n = 49) and observation group (n = 49). The patients in the control group were given routine treatment. The observation group was treated with montelukast sodium and loratadine on the basis of routine treatment. The therapeutic effect was compared between the two groups. Results: The total effective rate of the observation group was 97.96% (48/49), the effective rate of the control group was 73.47% (36/49), the difference was statistically significant (P <0.05) , Cough disappear time and wheeze and signs disappeared significantly shorter than the control group (P <0.05). Conclusion: In children with cough variant asthma, montelukast sodium combined with loratadine treatment is more effective than conventional treatment, which can significantly improve the therapeutic effect and improve clinical symptoms, which is worthy of clinical promotion and application.